Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

被引：88
|
作者：
Morrison, LH [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Dermatol OP06, Portland, OR 97239 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 51卷 / 05期
关键词：
D O I：
10.1016/j.jaad.2004.06.007
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.
引用
收藏
页码：817 / 819
页数：3
相关论文
共 50 条
  • [1] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
    Dupuy, A
    Viguier, M
    Bédane, C
    Cordoliani, F
    Blaise, S
    Aucouturier, F
    Bonnetblanc, JM
    Morel, P
    Dubertret, L
    Bachelez, H
    [J]. ARCHIVES OF DERMATOLOGY, 2004, 140 (01) : 91 - 96
  • [2] Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)
    Herrmann, G
    Engert, A
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (03) : 602 - 603
  • [3] Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): Five cases
    Antonucci, Angela
    Negosanti, Massimino
    Tabanelli, Michela
    Varotti, Claudio
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (03) : 178 - 183
  • [4] Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
    Marzano, Angelo V.
    Fanoni, Daniele
    Venegoni, Luigia
    Berti, Emilio
    Caputo, Ruggero
    [J]. DERMATOLOGY, 2007, 214 (04) : 310 - 318
  • [5] Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
    Cooper, HL
    Healy, E
    Theaker, JM
    Friedmann, PS
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) : 366 - 368
  • [6] Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris
    Faurschou, Annesofie
    Gniadecki, Robert
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2008, 47 (03) : 292 - 294
  • [7] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [8] Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed
    Belgi, AS
    Azeez, M
    Hoyle, C
    Williams, REA
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (01) : 143 - 143
  • [9] Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (Rituximab)
    Kong, HH
    Prose, NS
    Ware, RE
    Hall, RP
    [J]. PEDIATRIC DERMATOLOGY, 2005, 22 (05) : 461 - 464
  • [10] Rituximab (anti-CD20 monoclonal antibody) - Ultimate or first choice in pemphigus?
    Hertl, Michael
    Eming, Ruediger
    Borradori, Luca
    [J]. DERMATOLOGY, 2007, 214 (04) : 275 - 277
12345